Pregnancy ANtihypertensive Drugs: which Agent is best?

niversity of Birmingham0 个研究点目标入组 2,300 人开始时间: 2020年11月18日最近更新: 2024年7月15日

适应症

试验速览

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37700365/ (added 14/09/2023)

•1. Pregnancy 11+0 and 34+6 weeks’ gestation inclusive
•2. Diagnosis of pregnancy hypertension (chronic/gestational hypertension or pre-eclampsia)
•3. Clinician decision to initiate or continue use of antihypertensive drugs
•4. Aged 18 years or over
•5. Able to give informed consent
•For observational study:
•6. Women will be eligible to participate in the observational study at any gestational age up to and including 34+6 weeks. Women are able to take part in the observational study prior to 11+0 weeks gestation where the use of any antihypertensive drugs prescribed in clinical care will be recorded but will not form part of the interventional trial

•1. Contraindication to either labetalol or nifedipine
•2. Already taking both labetalol and nifedipine, and not able to be randomised to a single drug
•For observational study:
•3. Neither exclusion criterion for the trial are relevant for the observational study. Women contraindicated to either labetalol or nifedipine and/or women already taking both labetalol and nifedipine and not able to be randomised to a single drug, are eligible for the observational study

发起方